(Q37941507)

25 August 2017

1 reference

title

A review of the effects of memantine on clinical progression in Alzheimer's disease (English)

1 reference

25 August 2017

0 references

David Wilkinson

1

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 October 2011

1 reference

International Journal of Geriatric Psychiatry

25 August 2017

published in

1 reference

25 August 2017

volume

27

1 reference

25 August 2017

issue

8

1 reference

25 August 2017

page(s)

769-776

1 reference

Long-term course and effectiveness of combination therapy in Alzheimer disease

25 August 2017

cites work

1 reference

Cholinesterase inhibitors for Alzheimer's disease

21 January 2018

1 reference

Donepezil preserves cognition and global function in patients with severe Alzheimer disease

21 January 2018

1 reference

The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

21 January 2018

1 reference

Memantine (Ebixa) in clinical practice - results of an observational study.

21 January 2018

1 reference

Meta-analysis of six-month memantine trials in Alzheimer's disease.

21 January 2018

1 reference

Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients

21 January 2018

1 reference

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis

21 January 2018

1 reference

Alzheimer's disease in real life--the dementia carer's survey

21 January 2018

1 reference

Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan

21 January 2018

1 reference

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

21 January 2018

1 reference

Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies

21 January 2018

1 reference

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

21 January 2018

1 reference

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

Memantine enhances autonomy in moderate to severe Alzheimer's disease

21 January 2018

1 reference

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease

21 January 2018

1 reference

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

21 January 2018

1 reference

Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.

21 January 2018

1 reference

Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease

21 January 2018

1 reference

Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials

21 January 2018

1 reference

Memantine benefits functional abilities in moderate to severe Alzheimer's disease

21 January 2018

1 reference

Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease

21 January 2018

1 reference

Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.

21 January 2018

1 reference

7 January 2021

1 reference

7 January 2021

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

7 January 2021

Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.

1 reference

7 January 2021

Identifiers

DOI

10.1002/GPS.2788

1 reference

25 August 2017

1 reference